Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy
- PMID: 11502911
- DOI: 10.1212/wnl.57.3.445
Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy
Retraction in
-
Retraction: Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy.Neurology. 2020 May 5;94(18):804-805. doi: 10.1212/WNL.0000000000009359. Epub 2020 Mar 30. Neurology. 2020. PMID: 32229624 No abstract available.
Expression of concern in
-
Editors' note: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to prevent fractures in patients with MS; High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease.Neurology. 2018 Mar 27;90(13):627. doi: 10.1212/WNL.0000000000005202. Neurology. 2018. PMID: 29581332 No abstract available.
Abstract
Background: Bone loss and hypovitaminosis D are reported in patients taking antiepileptic drugs, but little is known about changes in bone and calcium metabolism from valproic acid (VPA).
Objective: To assess the relationship of VPA to bone mass and calcium metabolism in 40 adults with epilepsy on long-term VPA monotherapy, 40 age- and sex-matched epileptic patients taking phenytoin (PHT), and 40 healthy control subjects. Bone mineral density (BMD) of the second metacarpal was determined as T- and Z-scores.
Results: BMD reduction from control values was 14% (12% in men, 16% in women) with VPA and 13% (12% in men, 15% in women) with PHT. Among patients on VPA, nine (23%) had T-scores below -2.5 SD, suggesting osteoporosis; 15 (37%) had T-scores between -1 and -2.5 SD, suggesting osteopenia. Serum concentrations of calcium were significantly higher with VPA than in PHT or control groups. Serum concentrations of bone Gla protein (a bone formation marker) and pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP; a bone resorption marker) associated with either drug significantly exceeded control values. Z-scores for BMD in the VPA group correlated negatively with calcium and ICTP. High ICTP correlated positively with ionized calcium, implying that increased bone resorption caused the latter.
Conclusion: Long-term VPA monotherapy can increase bone resorption, leading to decreased BMD.
Comment in
-
Reader response: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to prevent fractures in patients with MS; High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease.Neurology. 2018 Mar 27;90(13):627-628. doi: 10.1212/WNL.0000000000005203. Neurology. 2018. PMID: 29581333 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical